Search hospitals > Connecticut > New Haven
Yale Cancer Center
Claim this profileNew Haven, Connecticut 06510
Global Leader in Solid Tumors
Global Leader in Tumors
Conducts research for Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
408 reported clinical trials
39 medical researchers
Summary
Yale Cancer Center is a medical facility located in New Haven, Connecticut. This center is recognized for care of Solid Tumors, Tumors, Cancer, Breast Cancer, Non-Small Cell Lung Cancer and other specialties. Yale Cancer Center is involved with conducting 408 clinical trials across 278 conditions. There are 39 research doctors associated with this hospital, such as Patricia M Lorusso, Alessandro Santin, Amer M. Zeidan, and Joseph W. Kim, MD.Area of expertise
1Solid Tumors
Global LeaderStage IV
Stage III
KRAS positive
2Tumors
Global LeaderStage IV
Stage III
MSI-H positive
Top PIs
Patricia M LorussoYale Cancer Center1 year of reported clinical research
Expert in Tumors
Studies Solid Tumors
21 reported clinical trials
37 drugs studied
Alessandro SantinSmilow Cancer Hospital at Yale New Haven4 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
15 reported clinical trials
24 drugs studied
Amer M. ZeidanYale Cancer Center3 years of reported clinical research
Studies Leukemia
Studies Myelodysplastic Syndrome
14 reported clinical trials
23 drugs studied
Joseph W. Kim, MDYale University8 years of reported clinical research
Studies Cancer
Studies Prostate Cancer
12 reported clinical trials
25 drugs studied
Clinical Trials running at Yale Cancer Center
Solid Tumors
Non-Small Cell Lung Cancer
Tumors
Cancer
Prostate Cancer
Squamous Cell Carcinoma
Breast Cancer
Pancreatic Cancer
Colorectal Cancer
Endometrial Cancer
Pembrolizumab
for Advanced Cancers
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.
Recruiting2 awards Phase 34 criteria
VLS-1488
for Advanced Cancer
This trial tests VLS-1488, a new drug for advanced cancers, to find the safest and most effective dose. It targets patients needing new treatment options and checks how the drug interacts with other medications and food.
Recruiting1 award Phase 1 & 26 criteria
PRTH-101 + Pembrolizumab
for Advanced Cancer
The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.
Recruiting1 award Phase 1
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Yale Cancer Center?
Yale Cancer Center is a medical facility located in New Haven, Connecticut. This center is recognized for care of Solid Tumors, Tumors, Cancer, Breast Cancer, Non-Small Cell Lung Cancer and other specialties. Yale Cancer Center is involved with conducting 408 clinical trials across 278 conditions. There are 39 research doctors associated with this hospital, such as Patricia M Lorusso, Alessandro Santin, Amer M. Zeidan, and Joseph W. Kim, MD.
Where is Yale Cancer Center located?
The Yale Cancer Center is located at 35 Park St, New Haven, CT 06519. For access, from I-95 or I-91, take the Route 34 connector and follow signs to the Air Rights Garage. From Wilbur Cross Parkway or Merritt Parkway, follow the respective directions to Route 34 or Ella T. Grasso Blvd, then to South Frontage Road, and enter the Air Rights Garage. Enter the building from the 4th floor of the parking garage and walk through the bridge to Smilow Cancer Hospital.
Who should I call to ask about financial aid or insurance network?
**Yale Cancer Center Hospital Financial Assistance and Insurance Departments**
**Financial Assistance:**
- **Phone:** 855-547-4584
- **Website:** [Financial Assistance Guidelines](https://www.ynhhs.org/patients-visitors/billing-insurance/FAP-guidelines)
- **Programs:**
- **Free Care:** For individuals with family income less than 2.5 times the federal poverty level.
- **Discounted Care:** For uninsured patients with family income ≤ 5.5 times the Federal Poverty Level.
- **Sliding Scale:** For insured patients with family income ≤ 5.5 times the Federal Poverty Level.
**Insurance:**
- **Phone:** 855-547-4584
- **Website:** [Insurance and Billing](https://www.ynhhs.org/patients-visitors/billing-insurance/)
- **Services:**
- Customer Service Staff available for billing and insurance inquiries.
- Patient Registrar contacts patients before visits for insurance information.
- Medication Assistance Program (MAP) for patients with high medication costs.
What insurance does Yale Cancer Center accept?
The Yale Cancer Center accepts a wide range of insurance plans, including but not limited to Aetna, Anthem BC/BS, Cigna, ConnectiCare, Medicaid, Medicare, TRICARE, UnitedHealthcare, and WellCare of Connecticut Medicare Advantage. It's crucial to verify with your insurance carrier that your chosen healthcare provider is in-network before scheduling an appointment. Failure to do so may result in out-of-pocket expenses for services rendered.
What awards or recognition has Yale Cancer Center received?
Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven are renowned for their pioneering contributions to cancer research, including the development of chemotherapy treatments and therapeutic agents. They boast the first university-based Medical Oncology section in the U.S. and lead in cancer biology research. With six research programs led by national experts, and as Connecticut's only National Cancer Institute-designated comprehensive cancer center, they offer advanced clinical trials and comprehensive care.